PLASMA-LYTE A IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for PLASMA-LYTE A IN PLASTIC CONTAINER (PLASMA-LYTE A IN PLASTIC CONTAINER).
Maintenance and restoration of fluid and electrolyte balance; provides isotonic crystalloid solution with sodium, potassium, magnesium, chloride, and acetate/bicarbonate precursors to buffer acidity.
| Metabolism | Acetate and gluconate are metabolized to bicarbonate primarily in the liver and kidneys; electrolytes are excreted unchanged via kidneys. |
| Excretion | Electrolytes and water are primarily excreted renally: sodium (90-95% filtered, reabsorbed), chloride (follows sodium), potassium (80-90% renal, 10% fecal), magnesium (30-50% reabsorbed, remainder excreted), acetate (metabolized to bicarbonate, ultimately renal). Fluid volume is regulated by renal mechanisms (ADH, aldosterone). Essentially 100% of administered volume and electrolytes are eliminated via kidneys under normal physiology. |
| Half-life | Not applicable as a single half-life; electrolytes have distribution and elimination phases governed by body stores and renal function. For water, elimination half-life is ~2-4 hours in euvolemic individuals with normal GFR. Clinically, infused volume distributes within ~30 minutes and is renally cleared over several hours. |
| Protein binding | None significant; electrolytes are free in plasma (sodium, chloride, potassium, magnesium are not protein-bound). Acetate is rapidly metabolized. |
| Volume of Distribution | Electrolytes: 0.2 L/kg for sodium and chloride (extracellular fluid); water: total body water ~0.6 L/kg. Clinical meaning: Vd of electrolytes approximates ECF volume; water distributes throughout total body water. |
| Bioavailability | Not applicable for IV route; bioavailability is 100% by definition. |
| Onset of Action | IV: Immediate (within seconds to minutes) for volume expansion and electrolyte effect, as infusion directly enters bloodstream. |
| Duration of Action | Volume effect lasts 1-2 hours in euvolemic patients; electrolyte effects persist until renal excretion. In hypovolemia, duration may be shorter due to rapid distribution. |
| Molecular Weight | Not applicable (mixture of electrolytes and water; individual components have low molecular weight, e.g., sodium 23 Da, chloride 35.5 Da, but as a solution, no single molecular weight applies) |
Intravenous infusion; adult dose is based on electrolyte and fluid requirements, typically 500-1000 mL/hour initially, then adjusted; maximum rate 30 mL/kg/hour.
| Dosage form | INJECTABLE |
| Renal impairment | No specific GFR-based dose adjustment; contraindicated in severe renal impairment with oliguria or anuria. |
| Liver impairment | No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment due to risk of electrolyte imbalances. |
| Pediatric use | Intravenous infusion; dose based on weight: 5-20 mL/kg/hour initially, adjusted according to clinical response and laboratory values; maximum 50 mL/kg/day. |
| Geriatric use | Use with caution due to increased risk of fluid overload and electrolyte disturbances; monitor renal function and adjust rate accordingly. |
| 1st trimester | Plasma-Lyte A is an isotonic crystalloid solution containing electrolytes in concentrations approximating human plasma. In the first trimester, it is generally considered safe when used as a volume expander or maintenance fluid, as it does not contain known teratogens. However, caution is advised due to potential volume overload and electrolyte imbalances, especially in patients with preeclampsia or cardiac disease. No specific fetal risks have been reported. |
| 2nd trimester | Similar to T1, use is considered safe for fluid and electrolyte replacement. Monitor maternal fluid status to avoid edema or pulmonary congestion. No evidence of adverse fetal effects. |
| 3rd trimester | Use during third trimester is generally safe for maternal volume expansion, but close monitoring is recommended, particularly in cases of hypertension or renal impairment. May affect amniotic fluid volume if maternal hemodynamics are altered. |
Clinical note
Comprehensive clinical and safety monograph for PLASMA-LYTE A IN PLASTIC CONTAINER (PLASMA-LYTE A IN PLASTIC CONTAINER).
| Placental transfer | Plasma-Lyte A components (water, electrolytes) are normal physiological constituents and cross the placenta freely as part of normal fluid and electrolyte exchange. The solution does not contain drugs or special additives that would alter placental transfer kinetics. In clinical use, fetal exposure is expected from maternal infusion but is considered safe at therapeutic doses. |
| Breastfeeding | Plasma-Lyte A is a crystalloid solution that does not contain drugs or substances that are significantly transferred into breast milk. It is considered compatible with breastfeeding. Electrolytes are normal constituents of breast milk, and infusion of this solution should not pose a risk to the nursing infant. However, consider maternal condition and need for fluid therapy. |
| Lactation Rating | Safe |
| Teratogenic Risk | No known teratogenic effects in any trimester. |
| Fetal Monitoring | Monitor serum electrolytes, fluid balance, and renal function. |
| Fertility Effects | No known impact on fertility. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any componentSevere hypernatremiaSevere hyperchloremiaSevere metabolic alkalosisPatients with clinically significant fluid overload (e.g., congestive heart failure, pulmonary edema)
| Precautions | Use with caution in patients with congestive heart failure, severe renal impairment, or conditions predisposing to fluid overload, Monitor serum electrolytes and acid-base balance regularly, Contains aluminum, which may be toxic with prolonged use in renal impairment, Risk of hyperkalemia in patients with renal failure or potassium-retaining medications |
| Food/Dietary | No specific food interactions. Maintaining hydration and electrolyte balance with dietary intake may be considered, but no restrictions are required. |
| Clinical Pearls | PLASMA-LYTE A is a balanced electrolyte solution indicated for fluid resuscitation; monitor serum electrolytes, especially in renal impairment. It contains acetate and gluconate as bicarbonate precursors; use cautiously in patients with lactic acidosis. Do not administer simultaneously with blood products through same IV line due to risk of clotting. Verify container integrity and that no leaks are present before use. |
| Patient Advice | This solution is given through a vein to restore body fluids and electrolytes. · Tell your healthcare provider if you have any allergies or medical conditions like kidney disease. · Inform your provider if you are pregnant or breastfeeding. · Report any signs of allergic reaction: rash, itching, swelling, severe dizziness, trouble breathing. · During infusion, notify your nurse if you experience pain, redness, or swelling at the IV site. · Do not stop the infusion or adjust the rate on your own. |
Loading safety data…